Clinical Trial Update: Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bemarituzumab in FGFR2b-positive advanced or metastatic stomach or gastroesophageal junction adenocarcinoma after at least one…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Bemarituzumab (bemarituzumab)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Metastatic Gastro-esophageal Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING